Literature DB >> 28917586

Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.

Yutaka Shiraishi1, Cai Xu2, Jinzhong Yang3, Ritsuko Komaki2, Steven H Lin4.   

Abstract

PURPOSE: To compare heart and cardiac substructure radiation exposure using intensity-modulated radiotherapy (IMRT) vs. proton beam therapy (PBT) for patients with mid- to distal esophageal cancer who received chemoradiation therapy. METHODS AND MATERIALS: We identified 727 esophageal cancer patients who received IMRT (n=477) or PBT (n=250) from March 2004 to December 2015. All patients were treated to 50.4Gy with IMRT or to 50.4 cobalt Gray equivalents with PBT. IMRT and PBT dose-volume histograms (DVHs) of the whole heart, atria, ventricles, and four coronary arteries were compared. For PBT patients, passive scattering proton therapy (PSPT; n=237) and intensity-modulated proton therapy (IMPT; n=13) DVHs were compared.
RESULTS: Compared with IMRT, PBT resulted in significantly lower mean heart dose (MHD) and heart V5, V10, V20, V30, and V40as well as lower radiation exposure to the four chambers and four coronary arteries. Compared with PSPT, IMPT resulted in significantly lower heart V20, V30, and V40 but not MHD or heart V5 or V10. IMPT also resulted in significantly lower radiation doses to the left atrium, right atrium, left main coronary artery, and left circumflex artery, but not the left ventricle, right ventricle, left anterior descending artery, or right coronary artery. Factors associated with lower MHD included PBT (P<0.001), smaller planning target volume (PTV; P<0.001), and gastroesophageal junction (GEJ) tumor (P<0.001). Among PBT patients, factors associated with lower MHD included IMPT (P=0.038), beam arrangement other than AP/PA (P<0.001), smaller PTV (P<0.001), and GEJ tumor (P<0.001).
CONCLUSIONS: In patients with mid- to distal esophageal cancer, PBT results in significantly lower radiation exposure to the whole heart and cardiac substructures than IMRT. Long-term studies are necessary to determine how this cardiac sparing effect impacts the development of coronary artery disease and other cardiac complications.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiac sparing; Esophageal cancer; IMRT; Proton beam therapy

Mesh:

Year:  2017        PMID: 28917586     DOI: 10.1016/j.radonc.2017.07.034

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  30 in total

Review 1.  Proton beam therapy for gastrointestinal cancers: past, present, and future.

Authors:  Shahed N Badiyan; Christopher L Hallemeier; Steven H Lin; Matthew D Hall; Michael D Chuong
Journal:  J Gastrointest Oncol       Date:  2018-10

2.  Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer.

Authors:  Steven H Lin; Brian P Hobbs; Vivek Verma; Rebecca S Tidwell; Grace L Smith; Xiudong Lei; Erin M Corsini; Isabel Mok; Xiong Wei; Luyang Yao; Xin Wang; Ritsuko U Komaki; Joe Y Chang; Stephen G Chun; Melenda D Jeter; Stephen G Swisher; Jaffer A Ajani; Mariela Blum-Murphy; Ara A Vaporciyan; Reza J Mehran; Albert C Koong; Saumil J Gandhi; Wayne L Hofstetter; Theodore S Hong; Thomas F Delaney; Zhongxing Liao; Radhe Mohan
Journal:  J Clin Oncol       Date:  2020-03-11       Impact factor: 44.544

3.  Dosimetric Comparison Between Carbon-ion Radiotherapy and Photon Radiotherapy for Stage I Esophageal Cancer.

Authors:  Yosuke Takakusagi; Daisaku Yoshida; Yohsuke Kusano; Kio Kano; Wataru Anno; Keisuke Tsuchida; Nobutaka Mizoguchi; Itsuko Serizawa; Hiroyuki Katoh; Koh Imura; Yoshiki Takayama; Shinichi Minohara; Tadashi Kamada
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

4.  Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation.

Authors:  Jacob S Witt; Justin C Jagodinsky; Yifei Liu; Poonam Yadav; Aleksandra Kuczmarska-Haas; Menggang Yu; James D Maloney; Mark A Ritter; Michael F Bassetti; Andrew M Baschnagel
Journal:  Am J Clin Oncol       Date:  2019-08       Impact factor: 2.339

Review 5.  Proton therapy for locally advanced non-small cell lung cancer.

Authors:  Olsi Gjyshi; Zhongxing Liao
Journal:  Br J Radiol       Date:  2019-08-20       Impact factor: 3.039

Review 6.  Effects of Radiotherapy in Coronary Artery Disease.

Authors:  Rose Mary Ferreira Lisboa da Silva
Journal:  Curr Atheroscler Rep       Date:  2019-11-19       Impact factor: 5.113

Review 7.  Cardiotoxicity of radiation therapy in esophageal cancer.

Authors:  Milan Vošmik; Miroslav Hodek; David Buka; Petra Sýkorová; Jakub Grepl; Petr Paluska; Simona Paulíková; Igor Sirák
Journal:  Rep Pract Oncol Radiother       Date:  2020-02-25

Review 8.  Proton therapy for patients with esophageal cancer: History, characteristics, clinical outcome and future direction of proton beam therapy.

Authors:  Masataka Karube; Hidetsugu Nakayama
Journal:  Glob Health Med       Date:  2021-06-30

9.  Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction.

Authors:  Cristina M DeCesaris; Melanie Berger; J Isabelle Choi; Shamus R Carr; Whitney M Burrows; William F Regine; Charles B Simone; Jason K Molitoris
Journal:  J Gastrointest Oncol       Date:  2020-08

Review 10.  Review of clinical results of charged-particle therapy for esophageal cancer.

Authors:  Takashi Ono
Journal:  Esophagus       Date:  2020-07-11       Impact factor: 4.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.